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ABSTRACT
Introduction. Diabetes mellitus (DM) is a major public 
health problem. Evidence has shown that aggressive 
control of hyperglycemia and associated risk factors 
reduces the risk of both macrovascular and micro-
vascular complications. The aim of this study was to 
determine the proportion of diabetes patients reaching 
the targets recommended by The American Diabetes 
Association (ADA) standards for diabetes care.
Methods and materials. This is a retrospective study, 
conducted at the diabetes outpatient clinics at TMC. 
For 628 patients with diabetes with at least two clinic 
visits in the 24 months before August 2010, we as-
sessed measurement and control of HbA1c, blood 
pressure, and lipid, the data were collected in a spe-
cially designed data sheet, and analyzed using SPSS 
program.
Results. 628 patients were studied. The mean age was 
49.6 ± 11.8 years; average duration of diabetes was 
6.5 ± 5.0 years. The mean last HbA1c was 8.2 ± 2.4%. 
75.1% attained a systolic blood pressure of < 140 and 
75.7% attained a diastolic blood pressure of < 90 mm Hg. 
Only 30.8% had LDL cholesterol of < 100 mg/dL and 
49.0% had a triglyceride level of < 150 mg/dL. The 
rate of annual foot examination, retinal examination 
screening, and urine microalbumin screening were low.
Conclusions. This study demonstrates a low rate of 
diabetes care targets achievement among patients 
with type 2 diabetes treated at TMC. (Clin Diabetol 
2017; 6, 6: 204–210)
Key words: glycemic control, diabetes type 2, Libya, 
TMC, targets, standards, quality of care, tertiary care
Introduction 
Diabetes mellitus (DM) is a major public health prob-
lem that is growing rapidly throughout the world, and 
its incidence is approaching epidemic proportions [1]. 
According to the International Diabetes Federation’s 
(IDF) statistics released, as many as 80% of people with 
diabetes live in developing countries, where, popula-
tion growth, ageing and, urbanisation with dramatic 
changes in lifestyle all contribute to the dramatic pace 
of the epidemic [2].
The prevalence of diabetes mellitus in Libya is not 
precisely known, although it has been estimated to be 
as high as 14.1% [3]. The prevalence of type 2 diabetes 
and impaired glucose regulation reported in a Libyan 
population based stepwise survey, which assessed the 
prevalence of cardiovascular risk factors among Libyans 
aged 25–64 was 23.7% [4].
Diabetes has been associated with chronic 
metabolic conditions such as obesity and metabolic 
syndrome, as well as related macrovascular and mi-
crovascular complications, such as coronary artery 
disease, peripheral vascular disease, stroke, diabetic 
neuropathy, renal failure and blindness [5, 6]. Diabetic 
complications result in significant disability, reduce life 
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expectancy and impose an enormous burden on socio-
economic and public health care systems [7–10]. Direct 
medical costs consist of resources used to manage the 
disease. Indirect costs include lost productivity caused 
by morbidity, disability and premature mortality [9, 10].
Hypertension, obesity, hyperlipidaemia and smok-
ing are important atherosclerotic risk factors which are 
more prevalent in diabetic patients and contribute to 
their high mortality compared with non-diabetic pa-
tients [11, 12]. Several clinical trials have demonstrated 
that intensive glycemic control effectively delays the 
onset and slows the progression of diabetic complica-
tions, such as nephropathy, retinopathy, and neuropa-
thy [13, 14]. Likewise, strong evidence has shown that 
aggressive control of associated risk factors such as 
hypertension, and hyperlipidemia reduces the risk of 
both microvascular and macrovascular complications 
[15, 16]. In addition, early detection of complications, 
by systematic annual screening, allows early diagnosis 
and early intervention [17–20]. The American Diabetes 
Association (ADA) recommends a set of diabetic care 
standards that advocate aggressive management of 
hyperglycemia, hypertension, and hyperlipidemia for 
patients with diabetes [21]. Despite the publication 
of the ADA and other guidelines, several studies have 
reported suboptimal target achievement and care pro-
vided to people with diabetes based on evidence-based 
quality of care standards [22, 23]. 
The aim of this study was to determine the propor-
tion of diabetes patients reaching the targets recom-
mended by the ADA standards for diabetes care. 
Methods and materials
This is a retrospective study, conducted at the 
diabetes outpatient clinics at the Tripoli Medical Center 
(TMC), a tertiary care center. Data collection was carried 
out in August and September 2010. The records of the 
first registered diabetic patients at the TMC diabetes 
clinic were reviewed. Patients were eligible for inclusion 
if they were of Libyan nationality, had type 2 diabetes, 
according to their medical records, and had at least 
two visits to the study clinic in the 24 months before 
August 2010. A total of 713 patients was included. 
Information about patient demographic charac-
teristics, smoking history, education, employment, 
duration of diabetes, presence of complications and 
the prescribed medication including lipid-lowering 
therapy and aspirin usage. Data for the most recent 
clinic visit were obtained using a chart review form. The 
following variables were assessed: height, weight, and 
blood pressure measurements during the most recent 
visit. Body mass index (BMI) was calculated using the 
formula: weight (kg)/height (m2). Aoutcome of foot 
examination, retinal examination, and urine micro-
albumin screening performed in the prior year were 
recorded. The last measured value of HbA1c, creatinine 
level, LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), 
triglyceride, and total cholesterol were collected. Also, 
frequency of performing these measurements within 
the prior year follow-up was assessed.
The targets used for this study were those specified 
by the ADA guidelines, namely HbA1c < 7%, LDL-C ≤ 100 
mg/dL, HDL-C ≥ 40 mg/dL, total cholesterol ≤ 200 mg/dL, 
triglycerides ≤ 150 mg/dL, systolic blood pressure 
≤ 130 mm Hg, and diastolic blood pressure ≤ 80 mm Hg, 
fasting blood glucose (FBG) ≤ 130 mg/dL.
Data were analyzed using the Statistical Pack-
age for Social Science (SPSS Inc., IBM, US), 19th ver-
sion. Continuous variables are expressed as mean ± 
standard deviation (SD) and range. Categorical data 
are expressed as numbers and percentages. Student’s 
t-test was used to compare continuous variables and 
qualitative variables were analyzed with the chi-square 
test or Fisher’s exact test. This study was carried out in 
accordance with the principles of the Helsinki Declara-
tion. A formal approval was obtained from institutional 
authorities. 
Results
The clinical characteristics of the 628 patients is as 
follows: mean age was 49.6 ± 11.8 years (18–81), 294 
(46.8%) were males, the mean disease duration was 
6.5 ± 5.0 years (range 1–34) and 300 (47.8%) had a 
positive family history of diabetes.
Smoking history was available for 442 (70.4%) 
of patients, where 69 (15.6%) were current smoker, 
28 (6.3%) were ex-smoker and 345 (78.1%) were non 
smokers. 67 (97.1%) of current smokers were males.
Body weight and height were documented for 370 
(58.9%) patients, mean BMI was 30.8 ± 8.4. Only 76 
patients (20.5%) had a BMI < 25 kg/m2, 118 patients 
(31.9%) were overweight with a BMI between 25–29 
kg/m2 and 176 patients (47.6%) were obese with a 
BMI ≥ 30 kg/m2.
Approximately 204 (32.5%) of patients had been 
on insulin, either alone or in combination with oral 
hypoglycemic agents (OHA), 292 (46.5%) were on met-
formin either alone or in combination with insulin and/ 
/or sulfonyleurea. 238 (37.9%) were on sulfonyleurea 
either alone or in combination with basal insulin and/ 
/or metformin.
Table 1 summarize the proportion of patients for 
whom the aspect of care have been documented in 
their medical records.
The mean fasting blood sugar was 195.0 ± 79.5 
mg/dL (range 31–721). HbA1c results in the previous 
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year were available for 371 (59.1%) patients and a 
mean frequency of testing was 1.5 ± 0.8 (range 1–5). 
The mean last HbA1c carried out for them was 8.2 ± 
2.4% (range 4.0–16). 98 (26.4%) achieved the recom-
mended goals for both blood glucose (HbA1c < 6.5%), 
57 (15.4%) achieved HbA1c < 7.5%, but more than 
6.5%, and 62 (16.7%) achieved HbA1c 7.5 – < 8.5 and 
in 154 (41.5%) the HbA1c > 8.5%. 
Documentation of blood pressure measurement 
was available for 570 (90.8%). The mean systolic blood 
pressure was 125.9 ± 17.2 (range 85–200) mm Hg, 
and the mean diastolic blood pressure was 79.6 ± 9.4 
(range 50–110) mm Hg. 
The distribution of patients’ systolic blood pres-
sure was: 428 (75.1%) ones with < 140 mm Hg, and 
142 (24.9%) ones with > 140 mm Hg (Fig. 1). The 
distribution of patients’ diastolic blood pressure was: 
431 (75.7%) ones with < 90 mm Hg and 138 (24.3%) 
ones with ≥ 90 mm Hg.
110 (17.5%) were on statins, 287 (45.7%) were 
on aspirin and 62 (9.9%) were on ACE inhibitors. The 
number of follow up in the previous year was 1.4 ± 
1.6 (range 0–7); 64 (10.2%) had peripheral neuropathy 
(PNP) based on symptoms or clinical examinations, 
27 (4.3%) had retinopathy, documentation of annual 
eye’s fundus examination available in 20 (3.2%). Symp-
toms of claudication were present among 14 (2.2%) 
patients. Examination of peripheral blood vessels done 
among 4 (0.6%) patients. Two patients (0.3%) had 
a history of amputations and 28 (4.5%) ones had 
ischaemic heart disease in the form of stable angina. 
Annual testing for protein urea was available among 
43 (6.8%) patients. Results of blood urea and creatinine 
levels was available among 319 (50.8%) patients. 
Table 1. The aspect of care documented in medical records at last visit
Variable No. (%) Variable No. (%)
Weight 543 (86.5) Triglyceride 404 (64.3)
BMI 370 (58.9) LDL cholesterol 312 (49.7)
Systolic blood pressure 569 (90.6) HDL cholesterol 311 (49.5)
Diastolic blood pressure 569 (90.6) Urea and/or creatinine 319 (50.8)
Fasting blood glucose 519 (82.6) Microalbuminuria 43(6.8)
HbA1c 371 (59.1)  Annual dilated fundus examination 20 (3.2)
Total cholesterol 393 (62.6)
Figure 1. Proportion of patients with type 2 diabetes mellitus reaching the targets of ADA standards of medical care in diabetes 
at Tripoli Medical Center. BP — blood pressure
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Results of total cholesterol, TG, HDL-C, LDL-C 
were available among 393 (62.6%), 404 (64.3%), 311 
(49.5%), 312 (49.7%) of patients’ files respectively. 
In those with available results, the mean serum total 
cholesterol was 187.4 ± 72.5 (101–973) mg/dL. 277 
patients (70.0%) had a total cholesterol < 200 mg/dL. 
The mean total serum triglyceride value was 170.4 
± 104.9 (40–937) mg/dL. 196 patients (49.0%) had 
a triglyceride level of < 150 mg/dL. Mean high density 
lipoprotein cholesterol (HDL) level was 47.4 ± 12.9 
(14.5–84.6) mg/dL. Only 80 female patients (46.2%) 
and 78 male patients (56.5%) had HDL level above the 
recommended of 50 mg/dL and 40 mg/dL. Low density 
lipoprotein cholesterol (LDL) level was 123.4 ± 50.6 
(37.4–452) mg/dL. Only seventy 96 patients (30.8%) 
had LDL cholesterol of < 100 mg/dL (Figure 1).
Discussion
Diabetes is a chronic metabolic condition, which 
is associated with increased morbidity, disability, and 
mortality, largely due to microvascular complications 
such as nephropathy, retinopathy and neuropathy and 
macrovascular complications such as coronary artery 
disease, peripheral vascular disease and stroke [6, 7].
Several clinical trials have shown that intensive 
glycemic control and the associated CV risk factors 
such as hypertension, and hyperlipidemia in diabetic 
patients reduces the risk of both microvascular and 
macrovascular complications [13–16].
Despite the broadly distributed diabetes care 
guidelines, which give clear recommendations to the 
glycemic, blood pressure and lipid targets in diabetic 
patients, several studies have indicated that achieve-
ment of these targets is suboptimal [22–25]. 
In the present study, only 59.1% of patients had at 
least one HbA1c test results available in their files, dur-
ing the year prior to last visit. The frequency of testing 
during that year was 1.5 ± 0.8. 
Regular HbA1c measurement is important for effec-
tive diabetes management. HbA1c reflects the average 
level of blood glucose over approximately 3 months and 
has strong predictive value for diabetes complications. 
ADA recommendation is to perform the A1C test at 
least two times a year in patients who have stable gly-
cemic control and more frequently in patients who are 
not meeting glycemic goals. HbA1c measurement is an 
essential indicator for optimal quality of diabetes care. 
Studies have found an association between adherence 
to HbA1c measurement and quality outputs [26–28]. 
Data from Kuwait found that doubling of the 
HbA1c measurements (from 30% to 63%) between 
2010 and 2012, was associated with a decrease in 
the rate of poorly controlled HbA1c from around 80% 
to 55% [29]. Our findings regarding glycemic control 
are comparable with those of studies in other Arab 
countries, 26.4% patients achieved HbA1c < 6.5% and 
41.8% ones achieved HbA1c < 7.5%. In a study from 
a university health center in Lebanon, target goal for 
HbA1c of < 7% was met in 28.4% individuals [30]. In 
a study from Saudi Arabia tertiary care hospital in Ri-
yadh only 21.8% patients achieved HBA1c < 7% [31]. 
Another study conducted in 28 Saudi health centers, 
all over the country, only 27% of patients achieved 
the target level of HbA1c of < 7% [32]. A study from 
a tertiary care setting in UAE in 2008, found that only 
20% achieved the target of HbA1c in that year [33]. 
In the present study, 41.5% of patients had HbA1c 
above 8.5%, this is less than the 54% reported in 
a study looking at diabetics in primary care settings in 
Saudia, and the 55.4% reported rate for poor control 
in Kuwait [29, 34]. 
Major clinical trials have shown that the target 
HbA1c goal, is difficult to maintain in clinical prac-
tice. According to the National Health and Nutrition 
Examination Survey (NHANES IV) 1999–2000, only 37% 
of participants with previously diagnosed diabetes 
achieved the target HbA1c goal of less than 7.0% [35]. 
In the United Kingdom Prospective Diabetes Study 
(UKPDS) HbA1c of 7.0% was achieved in only 50% of 
patients [36].
Barriers to achieving optimal glycemic goal include 
poor-compliance to diet, exercise and medications, lack 
of educations as well as cultural barriers. Clinical inertia 
may also contribute to it [37, 38].
In Tripoli medical center, diabetes outpatient clinic, 
the nurses are responsible for blood pressure and body 
weight measurement, on each visit before the consulta-
tion. 570 (90.8%) of our patients had their BP document-
ed, this rate is comparable to other studies, where more 
than 85% of patients attending the diabetic clinic had 
their blood pressure checked regularly [22, 23, 30, 39].
Blood pressure control is associated with signifi-
cantly lower risk of mortality, cardiovascular events, 
coronary heart disease, stroke, albuminuria, and 
retinopathy [6, 12, 15, 17, 19]. Previous ADA guide-
lines recommended strict blood pressure target of 
< 130/80 mm Hg in diabetic patients. In the Action 
to Control Cardiovascular Risk in Diabetes Blood Pres-
sure (ACCORD-BP) trial, blood pressure reduction to 
< 120 mm Hg compared with < 140 mm Hg, did not 
reduce mortality or overall cardiovascular outcomes, 
but significantly reduce stroke risk [40]. The current 
ADA recommendation is to achieve blood pressure 
levels < 140/90 mm Hg to reduce cardiovascular dis-
ease (CVD) mortality and slow chronic kidney disease 
progression [21].
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In the present study, the overall, systolic and dias-
tolic blood pressure goals of < 140/90 mm Hg were 
achieved in 65.8%, 75.1%, 75.7% patients respectively. 
29.0% patients achieved both systolic and diastolic 
blood pressure targets of < 130/80 mm Hg. In a study 
from Lebanon systolic and diastolic blood pressure 
goals of 135/85 mm Hg were met in 55.4%, 65.7%, of 
their studied patients [30]. In a study from a tertiary 
care center in Saudi Arabia, involving 1188 diabetic 
patients the overall, systolic and diastolic blood pres-
sure goals of < 130/80 were achieved in 39.0, 47.6 and 
74.6% of diabetic patients respectively [31]. 
Blood pressure control in diabetic patients is of-
ten challenging, and most patients with diabetes and 
hypertension require multiple-drug therapy to achieve 
blood pressure treatment goals [15, 21]. Only 35.8% 
of the people with diabetes that participated in the 
NHANES 1999–2000 survey reached the target of sys-
tolic blood pressure ≤ 130/80 mm Hg [35].
Several factors can contribute to poor blood pres-
sure control, clinical inertia, with the failure of the 
healthcare professionals to initiate or optimize drug 
therapy to achieve blood pressure targets [37, 38]. 
Poor compliance with prescribed medication is another 
important factor. Education and identifying and ad-
dressing the reasons for poor compliance is important 
to enhance medication adherence [37, 38].
In the present study, 62.6%, 64.3% of patients 
have documented total cholesterol and triglyceride 
measurement respectively, and about 49% had docu-
mented HDL or LDL measurement. Annual lipid meas-
urement was documented in 34% in Kuwait, 58% in 
Abu Dhabi, and 87% in Saudi Arabia [29, 31]. About 
51% of patients had their triglyceride above the target 
level, and 53.8% of female patients and 43.5% of male 
patients had their HDL cholesterol below the recom-
mended target level. Only 30.8% of our diabetics had 
LDL cholesterol of < 100 mg/dL, which meets the ADA 
goals for LDL cholesterol in diabetics.
Similar rates have been reported from a retrospec-
tive study from the United States of America, including 
data of 7.114 diabetic patients, with goal attainment 
rates for LDL < 100 mg/dL, HDL > 45 mg/dL, and for 
triglycerides < 150 mg/dL at 23%, 37%, and 33.8% 
respectively [39].
In a retrospective study from Oman including 430 
diabetic subjects from six general health centers, the 
proportion of patients meeting internationally recog-
nized goals for LDL cholesterol, HDL cholesterol and 
triglycerides were 15%, 32%, and 68% respectively [41].
Despite the evidence base and guideline recom-
mendations for specific preventive screening, such as 
ophthalmological examination, foot examinations, and 
screening for microalbuminuria, the documentation of 
foot examination, eye examination, and screening for 
microalbuminuria were low, annual testing for protein 
urea available in only 6.8% and dilated eye’s fundus 
examination in 3.2% of patients.
Diabetes needs a multidisciplinary team care ap-
proach to improve glycemic control. Nurses can play an 
important role in patient-oriented care, through educa-
tion and facilitating of patient adherence to treatment 
and annual screening procedures. 
Diabetes mellitus is a major health problem. In-
ternational guidelines and evidence recommended 
standards of care and targets for better outcomes. 
Challenges for good control lie with effectively im-
plementing them across the population. Continuing 
audit of diabetes services is an important tool to assess 
the current practice and highlighting deficiencies and 
thereby implement strategies to achieve the manage-
ment goals of a good quality care.
Limitations of this study 
First, the retrospective nature of the study, and 
the use of medical records to evaluate the care pro-
vided and patients’ outcomes, depend on the quality 
of documentation, and may underestimate the actual 
frequency of screening procedures due to lack of docu-
mentation. 
Second, factors that influence the outcome 
like patient’s compliance was not evaluated in 
this study.
Conclusion
Despite the adaptation of ADA standards of diabe-
tes care at our centre, this study showed that a large 
number of patients were not achieving the recom-
mended treatment targets. Further studies are needed 
to find out the causes of the gap between guidelines 
and practice and help in identifying the barriers to op-
timal diabetes care. Using a diabetes flow-sheet, which 
includes all the required targets of diabetes care, as 
advised by guidelines, would facilitate documentation 
and disease management. 
The role of nurses in diabetes care should be en-
hanced and nurses involvement in ordering routine 
laboratory and screening procedures would help ensure 
that, by the time patients are seen by the doctor, a 
number of recommended screening procedures have 
been done.
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